70 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
became effective on October 1, 2023, helping to simplify and streamline the billing and reimbursement of SYFOVRE.
Significant presence at multiple
8-K
EX-99.1
zcemlz588p78k
5 Oct 23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
7:15am
8-K
EX-1.1
ku95m
24 Mar 22
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8:18pm
424B5
gkp6jjg4xmtsz13t
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
e9ua7l2
23 Mar 22
Prospectus supplement for primary offering
5:14pm